SWOT Analysis for ReShape Lifesciences Inc.

Rising Net Cash Flow and Cash from Operating activity
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Company with Low Debt
Increasing Revenue every quarter for the past 2 quarters
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Increasing profits every quarter for the past 2 quarters
Stock with Low PE (PE < = 10)

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Lowest Momentum Scores (Technical Scores)
Oversold by Money Flow Index (MFI)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter